Fig. 4From: Utilizing the Hippo pathway as a therapeutic target for combating endocrine-resistant breast cancerIllustration of the roles of the Hippo pathway in ER + breast cancer. Overexpression of ZNF367 facilitates metastasis and activates Hippo/YAP signaling by inhibiting LATS [110]. Overexpression of USP9X stimulates cell proliferation by deubiquitinating and stabilizing YAP1 [111]. NE and EPI suppress breast cancer via rapid phosphorylation and cytoplasmic retention of YAP [112]. ZEB1, a transcriptional activator, interacts with YAP1 and promotes transcription [113]. The interaction of LATS1 and CRABP2 inhibits the ubiquitination of LATS1 to suppress cell invasion [106]. The STARD13-correlated ceRNA network regulates TAZ distribution, and it can inhibit the stem cell character of breast cancer through upregulation of LATS1/2 [114]Back to article page